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Abstract 24 
Schistosomiasis endangers the lives of greater than 200 million people every year and is 25 
predominantly controlled by a single class chemotherapy, praziquantel (PZQ).  Development 26 
of PZQ replacement (to combat the threat of PZQ insensitivity/resistance arising) or 27 
combinatorial (to facilitate the killing of PZQ-insensitive juvenile schistosomes) 28 
chemotherapies would help sustain this control strategy into the future. Here, we re-29 
categorise two families of druggable epigenetic targets in Schistosoma mansoni, the histone 30 
methyltransferases (HMTs) and the histone demethylases (HDMs). Amongst these, a S. 31 
mansoni Lysine Specific Demethylase 1 (SmLSD1, Smp_150560) homolog was selected for 32 
further analyses. Homology modelling of SmLSD1 and in silico docking of greater than four 33 
thousand putative inhibitors identified seven (L1 – L7) showing more favourable binding to 34 
the target pocket of SmLSD1 vs Homo sapiens HsLSD1; six of these seven (L1 – L6) plus 35 
three structural analogues of L7 (L8 – L10) were subsequently screened against 36 
schistosomula using the Roboworm anthelmintic discovery platform. The most active 37 
compounds (L10 - pirarubicin > L8 – danunorubicin hydrochloride) were subsequently tested 38 
against juvenile (3 wk old) and mature (7 wk old) schistosome stages and found to impede 39 
motility, suppress egg production and affect tegumental surfaces. When compared to a 40 
surrogate human cell line (HepG2), a moderate window of selectivity was observed for the 41 
most active compound L10 (selectivity indices - 11 for schistosomula, 9 for juveniles, 1.5 for 42 
adults). Finally, RNA interference of SmLSD1 recapitulated the egg-laying defect of 43 
schistosomes co-cultivated in the presence of L10 and L8.  These preliminary results 44 
suggest that SmLSD1 represents an attractive new target for schistosomiasis; identification 45 
of more potent and selective SmLSD1 compounds, however, is essential.  Nevertheless, the 46 
approaches described herein highlight an interdisciplinary strategy for selecting and 47 
screening novel/repositioned anti-schistosomals, which can be applied to any druggable 48 
(epigenetic) target encoded by the parasite’s genome.  49 
 50 
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1. Introduction  53 
Until a safe, reliable and efficacious prophylactic vaccine is developed, human 54 
schistosomiasis will continue to be primarily treated by anthelmintic chemotherapy.  55 
Currently, the drug of choice used in schistosomiasis control throughout endemic or 56 
emerging areas is praziquantel, a pyrazino-isoquinolone compound developed over 40 years 57 
ago as part of Merck’s effort in developing a new tranquilizer class (reviewed in (Cioli and 58 
Pica-Mattoccia, 2003)).  While praziquantel is safe, effective, relatively inexpensive to 59 
produce and operationally easy to deliver (Cioli et al., 2014), its inability to kill immature 60 
parasites (Wu et al., 2011) and its unclear mechanism of action (possibly as a G-protein 61 
coupled receptor antagonist (Chan et al., 2017)) raises concerns over its sustainability in 62 
helping to meet the World Health Organisation’s objective of regional schistosomiasis 63 
elimination by 2020 and beyond (WHO, 2012).  Added to these concerns is the spectre of 64 
praziquantel- insensitive or resistant parasites developing (Cupit and Cunningham, 2015).  65 
Therefore, new praziquantel replacement (if resistance develops) or combinatorial (with 66 
activity against immature parasites) anti-schistosomals are urgently needed for combatting a 67 
disease that currently affects greater than 200 million people annually (Colley et al., 2014). 68 
 Over the past decade, we, and others, have been involved in developing and 69 
applying high-throughput methods for selecting targets or compounds integral to early stage 70 
schistosome drug discovery projects (Kuntz et al., 2007; Caffrey et al., 2009; Fitzpatrick et 71 
al., 2009b; Peak et al., 2010; Rojo-Arreola et al., 2014; Mansour et al., 2016; Aguiar et al., 72 
2017).  Our specific efforts have identified (amongst others) arginase as a suitable 73 
schistosome drug target (Fitzpatrick et al., 2009a; Hai et al., 2014) and diterpenoids as 74 
potential, broad-acting anthelmintic compounds (Edwards et al., 2015; Crusco et al., 2018).  75 
Due to a growing realisation that schistosome development is regulated by epigenetic 76 
processes (Geyer and Hoffmann, 2012), we have now specifically focused on schistosome 77 
epigenetic targets as an additional repository for progressing anti-schistosomal efforts 78 
(Geyer et al., 2011; Cosseau et al., 2016; Geyer et al., 2018a; Geyer et al., 2018b; Roquis et 79 
al., 2018).  Other investigators have also interrogated epigenetic space (i.e. the processes 80 
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responsible for inheritable phenotypes that do not involve genome alterations) for 81 
schistosome drug discovery with most attention directed towards the identification and 82 
inhibition of histone modifying enzymes (HMEs) (e.g. (Azzi et al., 2009; Pierce et al., 2011; 83 
Pierce et al., 2012; Marek et al., 2013; Cabezas-Cruz et al., 2014; Carneiro et al., 2014).  As 84 
HMEs are critical regulators of developmental fate and disease pathogenesis in other 85 
metazoans (Butler et al., 2012), their selection as druggable epigenetic targets in early-stage 86 
schistosome drug discovery projects is well justified.  87 
 In this study, we reclassified two functionally opposing HME families in Schistosoma 88 
mansoni, the histone methyltransferases (HMTs) and histone demethylases (HDMs).  89 
Amongst these epigenetic enzymes, a S. mansoni lysine specific demethylase 1 (SmLSD1, 90 
Smp_150560) homolog was selected for an early stage drug discovery investigation based 91 
on the importance and role of Homo sapiens lysine specific demethylase 1 (HsLSD1) in 92 
essential biological processes (Maiques-Diaz and Somervaille, 2016; Ismail et al., 2018).  93 
Using SmLSD1 as a model, we illustrate how bioinformatics, cheminformatics, functional 94 
genomics and robotic whole organism screening can be synergistically applied to any 95 
druggable (epigenetic) target in the S. mansoni genome.   96 
  97 
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2. Materials and methods 98 
 99 
2.1. Ethics statement 100 
All procedures performed on mice (project license PPL 40/3700) adhered to the United 101 
Kingdom Home Office Animals (Scientific Procedures) Act of 1986 as well as the European 102 
Union Animals Directive 2010/63/EU and were approved by Aberystwyth University’s (AU) 103 
Animal Welfare and Ethical Review Body (AWERB).  104 
 105 
2.2. Parasite material 106 
A Puerto Rican strain (NMRI) of Schistosoma mansoni was used throughout the study and 107 
passaged between Mus musculus (Tuck Ordinary; TO) and Biomphalaria glabrata (NMRI 108 
albino and pigmented hybrid (Geyer et al., 2017)) hosts. Cercariae were shed from both B. 109 
glabrata strains by exposure to light in an artificially heated room (26 °C) for 1 hr and used to 110 
percutaneously infect M. musculus (180 cercariae/mouse for the generation of 7 wk old adult 111 
worms or 4000 cercariae/mouse for the generation of 3 wk old juvenile worms) (Smithers 112 
and Terry, 1965).  Cercariae were also used to generate mechanically transformed 113 
schistosomula (Colley and Wikel, 1974).  Adult (7 wk post infection) and juvenile (3 wk post 114 
infection) schistosomes were obtained from M. musculus by portal vein perfusion (Duvall 115 
and Dewitt, 1967).  Schistosomula, juvenile and adult worms were used for compound 116 
screening.  Adult worms were also used for RNA interference (RNAi). 117 
 118 
2.3. Identification of histone methyltransferases (HMTs) and histone demethylases 119 
(HDMs) 120 
The identification of S. mansoni HMTs and HDMs was performed using two methodologies.  121 
The first methodology focused on sequence similarity between the HMTs/HDMs from H. 122 
sapiens and S. mansoni.  Here, representative examples of H. sapiens HMTs/HDMs were 123 
downloaded from Uniprot (UniProt, 2009) and their protein sequences used as queries for 124 
protein BLAST (BLASTp) searches against the predicted protein database derived from the 125 
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S. mansoni genome (v 7.0) hosted in NCBI (https://blast.ncbi.nlm.nih.gov/Blast.cgi) and 126 
Wormbase-Parasite (Howe et al., 2017) using default settings.  The human HMTs/HDMs 127 
sequences (and their Uniprot access numbers) used were as follows: Histone-lysine N-128 
methyltransferase EZH2 (Q15910), Histone-lysine N-methyltransferase 2A (known as MLL1, 129 
Q03164), Histone-lysine N-methyltransferase SETD2 (Q9BYW2), Histone-lysine N-130 
methyltransferase SUV39H2 (Q9H5I1), N-lysine methyltransferase SMYD2 (Q9NRG4), 131 
Histone-lysine N-methyltransferase, H3 lysine-79 specific (known as DOT1L, Q8TEK3), 132 
Protein arginine N-methyltransferase 1 (Q63009), Histone-arginine methyltransferase 133 
CARM1 (Q86X55), Lysine-specific histone demethylase 1A (O60341), Lysine-specific 134 
demethylase 4A (known as Jmjd2, O75164), JmjC domain-containing protein 5 (Q8N371) 135 
and Bifunctional arginine demethylase and lysyl-hydroxylase JMJD6 (Q6NYC1).  For the 136 
BLASTp searches, full-length and catalytic domain peptide sequences were used as queries 137 
against the S. mansoni genome (v. 7.0). S. mansoni sequences were recognized as HMTs 138 
or HDMs only if they demonstrated high sequence similarity (an E value of 1e10-5 or lower) 139 
to human HMTs/HDMs and were observed (by visual inspection of the BLASTp pairwise 140 
alignments) to contain conservation over the catalytic domain as defined by InterPro (Finn et 141 
al., 2017), Pfam (Punta et al., 2012), PROSITE (Hofmann et al., 1999) or SMART (Schultz et 142 
al., 1998). 143 
To improve the robustness of our searches, a second methodology was applied 144 
based on the retention of conserved catalytic domain residues responsible for HMT and 145 
HDM enzymatic activity. Here, HMT and HDM domain identifiers were selected within 146 
Interpro, Pfam, PROSITE and SMART (see Supplementary Table 1).  Each signature was 147 
used as the query in Wormbase-Parasite BioMart to identify all putative S. mansoni proteins 148 
containing the aforementioned catalytic domains.    149 
The combination of these approaches led to the identification of 27 HMTs (three 150 
novel members) and 14 HDMs (three novel members) in S. mansoni. The HMTs were 151 
grouped into 20 Protein Lysine Methyl Transferases (PKMTs), 1 PR domain containing 152 
methyltransferase (PRDM), 1 DOT1 Like Histone Lysine Methyltransferase (DOT1L) and 5 153 
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Protein Arginine Methyl Transferases (PRMTs).  The HDMs were grouped into 3 Lysine 154 
Specific Demethylases (LSDs) and 11 Jumonji domain-containing proteins (JMJDs).  The 155 
most closely related Schistosoma haematobium and Schistosoma japonicum homologous 156 
sequences for these 27 SmHMTs and 14 SmHDMs were also identified by BLASTp 157 
interrogation of WormBase-Parasite.  For the BLASTp searches, full-length protein 158 
sequences of each SmHMT and SmHDM were used as queries against the S. haematobium 159 
and S. japonicum predicted protein datasets.  S. haematobium and S. japonicum sequences 160 
were recognized as the most closely related HMT and HDM homologs respectively 161 
(Sh/SjHMTs and Sh/SjHDMs) only if they demonstrated high sequence similarity (an E value 162 
of 1e10-50 or lower).  Only the top S. haematobium or S. japonicum hit (as defined by score) 163 
was included (Supplementary Table 2). 164 
 165 
2.4. Multiple sequence alignment and phylogenetic analyses 166 
Alignments of the catalytic domain amino acid sequences within the identified SmHMTs and 167 
SmHDMs were performed with MUSCLE ( ultiple Sequence Comparison by Log 168 
Expectation) using the default parameters (Edgar, 2004). The multiple sequence alignments 169 
were interrogated to determine regions of conservation using GBLOCKs 0.91b set to identify 170 
smaller block sizes with less strict flanking positions (Castresana, 2000).  For the HMT 171 
phylogenetic analysis, four regions covering a total of 50 amino acids were chosen by the 172 
GBLOCKS software, whereas the HDM analysis used three regions containing a total of 39 173 
amino acids selected by the GBLOCKs software.  Phylogenetic trees were constructed by 174 
MEGA7 using the neighbour-joining method based on the JTT matrix-based model with 175 
default settings and 1000 bootstrap replications (Kumar et al., 2016) and visualised using 176 
the Tree Of Life v1.0 (Ciccarelli et al., 2006). 177 
 178 
2.5. SmHMT and SmHDM domain classifications 179 
The amino acid positions of S. mansoni HMT and HDM domains having InterPro, 180 
SMART and Pfam identifiers were extracted from Wormbase-Parasite. These catalytic 181 
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domains were defined as follows: SET, Su(var)3-9, Enhancer-of-zeste and Trithorax domain 182 
for the PKMTs; DOT1, Disruptor of the telomeric silencing 1 for DOT1L; PRMT core, Protein 183 
Arginine (R) Methyltransferase core domain for PRMTs; AOL, Amine Oxidase-like domain 184 
for LSDs; JMJC, Jumonji C domain and JMJN, Jumonji N domain for the JMJDs.  The start 185 
and end position of these domains were confirmed, or modified if needed, according to the 186 
multiple sequence alignments. 187 
 The architecture of these proteins was then populated with other N-terminal and/or 188 
C-terminal domains known from the literature to be associated with the aforementioned 189 
catalytic domains.  Graphical representation of these domains within the schistosome HMTs 190 
and HDMs was prepared using Illustrator for Biological Sequences (IBS, (Liu et al., 2015)).  191 
 192 
2.6. Smhmt and Smhdm transcription profiles 193 
Data from the 37,632 element S. mansoni long-oligonucleotide DNA microarray studies of 194 
Fitzpatrick et al. (Fitzpatrick et al., 2009b) were interrogated to find the expression profile of 195 
the 27 Smhmts and 14 Smhdms across 14 different lifecycle stages.  Here, Log2 normalised 196 
gene expression data were subjected to hierarchical agglomerative clustering (Euclidean 197 
distance and complete linkage) using the R statistical programming language and the 198 
Bioconductor package gplots (Gentleman et al., 2004). The analysed data were then 199 
illustrated as a heat map.  Raw and normalised fluorescent intensity values are available via 200 
Array Express under the experimental accession number E-MEXP-2094.  Oligonucleotide 201 
probes corresponding to each Smhmt and Smhdm as well as their corresponding log2 202 
expression values are found in Supplementary Table 2. 203 
 204 
2.7.  Homology modelling 205 
The homology model of Smp_150560 (S. mansoni Lysine Specific Demethylase 1, 206 
SmLSD1) was prepared with the Molecular Operating Environment (MOE) 2015.10 207 
(Chemical Computing Group, 2018) homology tool using a single template approach.  The 208 
template selected for SmLSD1 was the three-dimensional structure of H. sapiens LSD1 209 
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(HsLSD1; Protein Data Bank – PDB - (Berman et al., 2000) identification code 2V1D, chain 210 
A) (Forneris et al., 2007).  The sequence identity between SmLSD1 and the human template 211 
was 41% with a sequence coverage over 60%, hence well within the acceptable range for 212 
comparative modelling techniques (Baker and Sali, 2001). 213 
An induced fit option was selected to take into account the presence of the substrate 214 
(histone H3) and cofactor (Flavin Adenine Dinucleotide, FAD).  Ten different intermediate 215 
models were built and minimised using Amber94 before refining the final model, which 216 
generates a Cartesian average of the 10 generated intermediates.  The final model was 217 
confirmed by I-TASSER (Iterative Threading ASSEmbly Refinement) (Yang et al., 2015), 218 
Robetta (Kim et al., 2004) and SWISS-MODEL (Waterhouse et al., 2018) with the overall 219 
quality of the model evaluated by RAMPAGE Ramachandran Plot analysis 220 
(http://mordred.bioc.cam.ac.uk/~rapper/rampage.php).  221 
 222 
2.8. Compound docking to SmLSD1 223 
Compounds capable of binding to SmLSD1 were identified using Glide docking software 224 
within Maestro v10.1 (Maestro, 2015).  To initiate docking in either software suite, selection 225 
of compounds and preparation of targets was necessary (Supplementary Figure 1).  Firstly, 226 
a library of commercially available compounds was downloaded from Specs 227 
(www.specs.net, natural compounds and fragment-based library) in sdf format.  These 228 
compounds (4,532) were then processed by Maestro’s LigPrep tool to include all the partial 229 
charges, the appropriate protonation state at the defined pH, the proper tautomeric states, 230 
the bond lengths and angles.  Secondly, the crystal structure of HsLSD1 was downloaded 231 
from PDB (PDB code 2V1D) and the three-dimensional structure of SmLSD1 was prepared 232 
by homology modelling as described above. The two structures were processed with the 233 
Schrödinger Protein Preparation Wizard tool using the OPLS_2005 force field to assign 234 
partial charges, bond orders, cap residues, add hydrogen atoms, fill in missing loops as well 235 
as side chains and to minimize the protein structure relieving any steric clashes.  Thirdly, a 236 
12 Å docking grid (inner-box 10 Å and outer-box 22 Å) was computationally built using, as a 237 
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centroid, the structure of the histone H3 that was used for the co-crystallisation of HsLSD1 238 
as well as for the induced-fit homology modelling of SmLSD1. 239 
Docking simulations for virtual screening of Specs compounds with SmLSD1 were 240 
next performed in Glide using the standard precision function (SP; all 4,532 compounds) and 241 
the results were refined using the more accurate extra precision (XP) function.  In all cases, 242 
default parameters were selected and ten output poses (conformations) per input ligand 243 
were included in the solution.  From the 2,500 solutions (conformations) ranked according to 244 
the Glide XP scoring function, 500 distinct compounds were identified and retained for 245 
HsLSD1 (PDB code 2V1D) docking.  The compounds with a more favourable docking score 246 
(XP score) for SmLSD1 compared to HsLSD1 were considered hits and the top 100 were 247 
selected for further processing. 248 
  SmLSD1 docking results (Glide XP) of the 100 selected compounds were saved in 249 
a single mol2 file and the docking poses were visually inspected for their binding mode in 250 
MOE. The docking poses of each of the 100 selected compounds were evaluated according 251 
to the ability of each compound to occupy the target pocket, the number of interactions 252 
between the compound and the target protein, the selection of different chemical scaffolds 253 
and the potential chemical instability or toxicity (i.e. presence of a nitro group) of the 254 
compounds.  From this iterative approach, seven putative SmLSD1 inhibitors (L1-L7) and 255 
three structural L7 analogues (L8 - L10) were identified (Supplementary Table 3). 256 
 257 
2.9.  Compounds and compound storage 258 
Six of the seven putative SmLSD1 inhibitors (L1-L6) were obtained from Specs 259 
(Supplementary Table 3).  As L7 was not commercially available, three structural analogues 260 
(L8 - L10) were purchased from Sigma Aldrich (UK) (Supplementary Table 3).  All 261 
compounds were obtained as powder stocks, solubilised in DMSO to a stock concentration 262 
of 10 mM and stored at -20 °C until required.  Posi tive controls for S. mansoni screens 263 
included praziquantel (Sigma-Aldrich, UK) and/or auranofin (Sigma-Aldrich, UK), which were 264 
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also diluted in DMSO to a stock concentration of 10 mM and working concentration of 1.6 265 
mM. 266 
 267 
2.10. Whole organism screening of S. mansoni schistosomula, juveniles and adults 268 
Mechanically-transformed schistosomula were screened on the Roboworm platform as 269 
previously described (Nur et al., 2017; Crusco et al., 2018).  Primary screens of L1 - L6 and 270 
L8 - L10 were performed at 10 µM final concentration (0.625% DMSO); hits (L8 and L10) at 271 
this concentration were subjected to further titration in a secondary screen (10 µM, 5 µM, 2.5 272 
µM, 1.25 µM and 0.625 µM in 0.625% DMSO).  Negative (0.625% DMSO) and positive (10 273 
µM auranofin in 0.625% DMSO) control wells were included in all schistosomula screens.  274 
For primary screens, each putative SmLSD1 inhibitor was tested in duplicate.  For 275 
secondary screens, each concentration of L8 and L10 was tested in duplicate and the 276 
titration was repeated three times. 277 
Juvenile worm screens (15-20 worms/well) were performed in a 96 well plate format 278 
(flat bottom) containing a final volume of 200µL of media (DMEM (Gibco, Paisley, UK) 279 
supplemented with 10% v/v Hepes (Sigma-Aldrich, Gillingham, UK), 10% v/v Foetal Bovine 280 
Serum (Gibco, Paisley, UK), 0.7% v/v 200 mM L-Glutamine (Gibco, Paisley, UK) and 1X v/v 281 
penicillin-streptomycin (Fisher Scientific, UK)).  To each well, L8 and L10 were added at the 282 
following concentrations: 20 µM, 15 µM, 10 µM, 5 µM and 2.5 µM and 1.25 µM (in 1.25% 283 
DMSO). Parasites were cultured at 37 °C in an atmosphere containing 5% CO2 for 72 hr at 284 
which time worm motility was scored between 0-4: 0 = dead, 1 = movement of the suckers 285 
only and slight contraction of the body, 2 = movement at the anterior and posterior regions 286 
only, 3 = full body movement but sluggish and 4 = normal movement.  DMSO (negative 287 
control, 1.25% DMSO) and praziquantel (positive control, 10 µM in 1.25% DMSO) were 288 
included in these juvenile worm assays. 289 
Adult worm screens were initiated as described previously (Crusco et al., 2018).  290 
Briefly, schistosome pairs (3 pairs/well in a 48-well microtiter plates) were co-cultivated with 291 
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L8 and L10 (two-fold titrations between 50 µM - 6.25 µM in 1.25% DMSO) for 72 h at 37 °C 292 
in a humidified atmosphere containing 5% CO2.  As controls, schistosome pairs co-cultivated 293 
in DMSO (1.25%) and praziquantel (10 µM in 1.25% DMSO) were included in these assays.   294 
After 72 hr, motility was scored according to defined WHO-TDR metrics (Ramirez et al., 295 
2007) and eggs deposited in wells were enumerated.  296 
 297 
2.11.  Preparation of S. mansoni worms for scanning electron microscopy (SEM) 298 
Adult schistosomes were cultivated (as described above) in sub lethal concentrations of L10 299 
(12.5 µM) for 72 hr.  Afterwards, schistosomes were prepared for SEM as previously 300 
described (Crusco et al., 2018).  301 
 302 
2.12.  HepG2 culture and MTT assay 303 
Overt cytotoxicity of L8 and L10 was assessed on human HepG2 cells as described 304 
previously (Crusco et al., 2018).  Briefly, 2 x 104 cells/well were seeded in black walled 96-305 
well microtiter plates (Fisher Scientific, Loughborough, UK) and incubated for 24 hr at 37 °C 306 
in a humidified atmosphere containing 5% CO2.  To each well, L8 and L10 was subsequently 307 
added to obtain final concentrations (in 1.25% DMSO) of 200 µM, 100 µM, 75 µM, 50 µM, 20 308 
µM, 10 µM and 1 µM; negative (DMSO; 1.25%) and positive (1% v/v Triton X-100) control 309 
wells were also included. Following a further incubation for 24 hr, the MTT assay was 310 
performed as previously described (Crusco et al., 2018; Nur et al., 2017).  Dose response 311 
curves to calculate CC50 values were generated in GraphPad Prism 7.02. 312 
 313 
2.13 RNA interference (RNAi) 314 
Following the perfusion of 7-week infected mice, adult worms were recovered and RNAi 315 
performed as previously described (Geyer et al., 2011).  Smlsd1 and non-specific luciferase 316 
(Luc) siRNA duplexes were purchased from Sigma (siRNA sequences defined in 317 
Supplementary Table 4).  Briefly, 5 worm pairs were transferred to 4mm electroporation 318 
cuvettes containing DMEM (5.4 g/L D-Glucose, Sigma) supplemented with 2 mM L-319 
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glutamine, 10,000 Units/ml penicillin and 10,000 µg/ml streptomycin. siRNA duplexes (5 µg) 320 
were subsequently added and worms were electroporated with a single pulse at 125V for 321 
20ms using a ECM-830 Square Wave Porator (BTX).  Worms were cultured at 37 °C in 322 
DMEM (5.4 g/L D-Glucose, Sigma) supplemented with 10% fetal calf serum, 2 mM L-323 
glutamine, 10,000 Units/ml penicillin and 10,000 µg/ml streptomycin in an atmosphere of 5% 324 
CO2 with a 70% media exchange performed every 24 hr.  At 48 hr, worms were processed 325 
for quantitative reverse transcription PCR (qRT-PCR); numbers of eggs produced at this 326 
time point were also quantified.  Separate worms were maintained in continuous culture for 327 
up to 168 hr, after which time, deposited eggs were also quantified.    328 
 329 
2.14. Quantitative reverse transcription PCR (qRT-PCR) 330 
Following RNAi with siSmlsd1 and siLuc, mixed-sex adult worms were incubated for a total 331 
of 48 hr before processing them for RNA isolation. Briefly, worms were homogenised using a 332 
TissueLyser LT (Qiagen, UK) in TRIzol Reagent (Invitrogen, UK) before isolation of total 333 
RNA using the Direct-zol RNA Kit (Epigentek, UK). cDNA was then generated, qRT-PCR 334 
performed and data analysed as previously described (Fitzpatrick et al., 2009b).  qRT-PCR 335 
primers are defined in Supplementary Table 4. 336 
 337 
2.15. Statistics 338 
All Statistical analyses were conducted using GraphPad Prism 7 software. To determine 339 
significant differences amongst more than two population means, a Kruskal-Wallis ANOVA 340 
followed by Dunn’s multiple comparisons test was used.  To determine significant 341 
differences amongst two population means, a student’s t-test assuming unequal variance 342 
was performed.  343 
 344 
 345 
  346 
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3. Results and discussion 347 
3.1. Re-characterisation of S. mansoni histone methyltransferases (HMTs) and histone 348 
demethylases (HDMs) 349 
Recent studies have suggested that components of the schistosome epigenetic machinery, 350 
especially histone modifying enzymes (HMEs), should be considered as viable next-351 
generation anthelmintic targets (Pierce et al., 2012; Cabezas-Cruz et al., 2014). The 352 
identification and optimisation of compounds that affect S. mansoni histone acetyl 353 
transferase- (HATs) or histone deacetylase- (HDAC) activities has been the predominant 354 
focus of such investigations to date (Andrews et al., 2011; Lancelot et al., 2013; Marek et al., 355 
2013; Carneiro et al., 2014; Schiedel et al., 2015).  However, we and others have pursued 356 
the biological characterisation and chemotherapeutic targeting of two other epigenetic 357 
families in S. mansoni, the histone methyltransferases (HMTs) and the histone 358 
demethylases (HDMs) (Mansure et al., 2005; Cosseau et al., 2016; Anderson et al., 2017; 359 
Roquis et al., 2018).   The justification for this approach originates from current clinical 360 
interest in developing inhibitors of the homologous human enzymes for therapeutic use in 361 
treating cancer and other diseases (McAllister et al., 2016; Zahnow et al., 2016; Hauser et 362 
al., 2018).  Therefore, identification of selective schistosome HMT and HDM inhibitors could 363 
lead to the development of therapeutic strategies for disrupting parasite processes (e.g. 364 
reproduction, egg laying) responsible for schistosomiasis pathology and transmission. 365 
The initial step in this process was to first identify all putative S. mansoni HMT and 366 
HDM family members (Figure 1).  As previously reviewed (Cheng et al., 2005; Pedersen and 367 
Helin, 2010), HMTs are responsible for adding a methyl group to N-terminal tails of histone 368 
(and other) proteins whereas HDMs remove this post-translational modification (Figure 1A).   369 
Within the HMT family are two subfamilies; the Protein Lysine Methyltransferases (PKMTs), 370 
which catalyse the methylation of lysine residues and the Protein Arginine 371 
Methyltransferases (PRMTs), which enzymatically modify arginine residues.  With the 372 
exception of DOT1 (Disruptor of telomeric silencing, (Singer et al., 1998)) and PRDM (PRDI-373 
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BF1 and RIZ homology domain, (Fog et al., 2012)) containing HMTs, the catalytic region of 374 
all other PKMTs contain a well-conserved SET (Su(var)3-9, Enhancer-of-zeste 375 
and Trithorax) domain (Figure 1B).  In contrast, the enzymatically active region of all PRMTs 376 
is designated as the PRMT core (Figure 1B).   377 
The use of the SET domain signature (defined by Interpro, Pfam, PROSITE and 378 
SMART databases, Supplementary Table 1) led to the identification of 20 putative S. 379 
mansoni PKMTs in Wormbase parasite (Figure 1C, light blue Smps).  Reassuringly, these 380 
results confirmed previous analyses of S. mansoni SET-domain containing PKMTs 381 
(Cabezas-Cruz et al., 2014) but also identified two new putative members (Smp_149380 382 
and Smp_148360, highlighted in red boxes, Figure 1C).  The identification of these 20 S. 383 
mansoni PKMTs was confirmed by a second approach based on sequence similarities to 384 
human SET-domain containing PKMTs.  Here, using human PKMT sequences (full length 385 
and catalytic domains) to query the S. mansoni genome, only these 20 SmPKMTs were 386 
found (E value ≤ 1e10-5).  387 
Our sequence similarity searches also identified a PRDM-containing PKMT 388 
(Smp_016750, Figure 1C, dark blue Smp outlined in red box). The PRDM family is related to 389 
SET domain-containing PKMTs, but with some noticeable differences (reviewed in 390 
(Hohenauer and Moore, 2012)).  While the catalytic domain of this protein family has 20-391 
30% sequence similarity to the SET domain, PRDM members also contain a variety of 392 
different amino acid motifs that differentiate them from other PKMTs (Hohenauer and Moore, 393 
2012). Previously, it was suggested that S. mansoni contains 6 PRDMs (Vervoort et al., 394 
2016).  However, only one of these proteins (Smp_016750, red box surrounding dark blue 395 
ID in Figure 1C) fitted the criteria used in this study (a divergent SET domain along with 396 
other motifs including F/Y/IGP/V and ExNL) (Hohenauer and Moore, 2012). Whether this 397 
protein is a catalytically active PKMT is currently unknown.  398 
In addition to the 20 SET-domain and one PRDM-domain containing PKMTs, the 399 
complementary approaches used in this study confirmed the presence of only one DOT1L 400 
(Smp_165000, dark orange) PKMT and 5 PRMTs (Smp_070340, 029240, 025550, 171150 401 
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and 337860, light orange) (Figure 1C) (Cabezas-Cruz et al., 2014).  A detailed architectural 402 
analysis of each HMT family member was conducted and demonstrated a rich collection of 403 
functional domains important for translating histone methylation into functional cellular 404 
phenotypes (Supplementary Figure 2). 405 
Similar to HMTs, HDMs are usually grouped into two distinct subfamilies based on 406 
their proposed mechanisms of action: the Lysine Specific Demethylases (LSDs), which are 407 
FAD-dependent amine oxidases and the Jumonji C domain-containing demethylases 408 
(JMJDs), which are Fe(II) and 2-oxoglutarate-dependent enzymes. For identification 409 
purposes, the catalytic domain signatures of these two subfamilies are the Amine Oxidase-410 
Like (AOL) domain (LSDs) and the Jumonji C terminal domain (JmjC, usually associated 411 
with another domain known as Jumonji N terminal - JmjN) (Figure 1B and Supplementary 412 
Table 1).  In the case of schistosome LSDs, BLASTp searches in NCBI using the full protein 413 
sequence of the human Lysine-specific histone demethylase 1A (O60341) and Lysine-414 
specific histone demethylase 1B (Q8NB78) led to the confirmation of Smp_150560 (E value 415 
= 2e-155) as a putative SmLSD1 and Smp_160810 (E value = 1e-06) and Smp_162940 (E 416 
value = 1e-08) as putative SmLSD2s (Figure 1B, purple Smps).  In support of these findings, 417 
the domain architecture of these three Smps were further analysed for additional 418 
discriminatory motifs that are characteristic of LSD1 and LSD2 family members 419 
(Supplementary Figure 2).  Here, a SWIRM (Swi3p, Rsc8p, and Moira) domain was found in 420 
all three Smps, but a TOWER domain was only present in Smp_150560.  In addition, both 421 
Smp_160810 and Smp_162940 contained two zinc finger (zf-C4H2C2 and zf-CW) domains.  422 
Based on these features (Ismail et al., 2018), Smp_150560 appears to be the only LSD1 423 
present in the S. mansoni genome.  424 
Regarding the JMJDs, the use of JmjC signatures (Supplementary Table 1) led to the 425 
identification of 11 putative S. mansoni members; three of these also contain the JmjN 426 
domain (Figure 1C, green Smps and Supplementary Figure 2). The most interesting result 427 
was the identification of three previously unknown JMJDs (Smp_342360, Smp_241580 and 428 
Smp_333400; highlighted within red boxes in Figure 1C and Supplementary Figure 2).  The 429 
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domain architecture of these SmHDMs was analysed in detail (Supplementary Figure 2) 430 
and, similar to the SmHMTs, illustrated the diversity of motifs used for regulating histone 431 
(and other protein) methylation states.  432 
Using these bioinformatics-led approaches, the putative schistosome HMTs/HDMs 433 
previously identified (Pierce et al., 2012; Cosseau et al., 2016) were confirmed and an 434 
additional six new HMTs/HDMs were identified.  Based on these analyses, the S. mansoni 435 
histone methylation machinery is comprised of 27 HMTs and 14 HDMs.  Homologous S. 436 
haematobium and S. japonicum HMTs and HDMs (ShHMT/SjHMT or ShHDM/SjHDM), 437 
when found, were also recorded (Supplementary Figure 2)  438 
 439 
3.2. Longitudinal transcriptional analysis of S. mansoni HMTs and HDMs. 440 
As there has been no comparative gene expression profiling for all SmHMTs or SmHDMs, 441 
transcript abundances of these epigenetic products were inferred from historical DNA 442 
microarray data (Fitzpatrick et al., 2009b) (Figure 2).  When compared to the only previous 443 
study examining gene expression for a single SmHMT family member (SmPRMT1, 444 
Smp_029240), our results are broadly in agreement for similarly profiled lifecycle stages 445 
(adult female and male parasites; female > male) (Mansure et al., 2005).  However, our 446 
more extensive lifecycle analysis of this and all other SmHMTs (Figure 2A) and SmHDMs 447 
(Figure 2B) suggests that wide modulation of these family’s gene expression occurs 448 
throughout schistosome development.  Noticeably, all members (except the SET domain 449 
containing PKMTs Smp_144180, Smp_160700 and Smp_342100) seem to be expressed in 450 
low abundance in the daughter sporocyst lifecycle stage.  Maximal abundance of any 451 
SmHMT or SmHDM was found in the sexually-mature adult lifecycle stage (5 wk old); here, 452 
the three SET domain containing PKMTs Smp_000700, Smp_078900 and Smp_210650 as 453 
well as the two JmjC containing JMJDs Smp_156290 and Smp_019170 and the AOL-454 
containing LSD Smp_150560 are all found in higher abundance when compared to other 455 
lifecycle stages.  In addition to spatial expression differences and transient variations in 456 
SmHMT and SmHDM activities, these longitudinal gene expression results are likely 457 
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contributing to the previously reported developmental changes in schistosome histone 458 
methylation states and are required (together with other post-translational histone 459 
modification) for normal developmental progression in schistosomes (Roquis et al., 2015; 460 
Roquis et al., 2018).  One SmHDM, the LSD1 homolog Smp_150560 (SmLSD1, Figure 3), 461 
was chosen as a target for further cheminformatics, functional genomics and whole 462 
organism anthelmintic studies due to the important role of human LSD1 in oncogenesis and 463 
development (Ismail et al., 2018). 464 
 465 
3.3. In silico docking of compounds to SmLSD1. 466 
Secondary structural analysis of SmLSD1 predicted a 1164 AA protein containing a N-467 
terminal SWIRM domain (AAs, 165-287) as well as a C-terminal amine oxidase like (AOL) 468 
domain (AAs, 379-824 and 909-1136) (Figure 3A).  Similar to HsLSD1 (Ismail et al., 2018), 469 
the AOL domain of SmLSD1 is interrupted by a Tower domain (AAs, 825-908).  To progress 470 
the cheminformatics selection of putative compounds that may interfere with SmLSD1 471 
activity, tertiary structural analysis was next conducted (Figure 3B).  However, as the 472 
structure of SmLSD1 is not currently known, we created a homology model of this 473 
schistosome HDM using chain A of HsLSD1 (PDB entry 2V1D; SmLSD1 and HsHSD1 474 
contain 41% sequence identity over 71% of their entire length), co-crystallised with AA 475 
residues 1-16 of histone 3 (H3; position 4 is a methylated Lys) and Flavin Adenine 476 
Dinucleotide (FAD), as a template.  The SmLSD1 model revealed that the SWIRM domain 477 
(orange) adopts a six-helical architecture and packs closely to the AOL domain (green).  478 
While the SWIRM domain function is still undefined, it is likely involved in DNA or protein 479 
binding (Aravind and Iyer, 2002).  The AOL domain (responsible for SmLSD1 catalytic 480 
activity) is folded into two distinctive subdomains so that the cofactor binding pocket (where 481 
FAD is located, spheres) and the target-binding pocket (where methylated Lys, yellow stick, 482 
of H3 is located) are brought together.  The Tower domain (blue) of SmLSD1 is likely 483 
responsible for establishing higher order protein interactions (Amente et al., 2013).  The 484 
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magnified surface structure of the target pocket is shown and represents the location where 485 
in silico binding of potential SmLSD1 inhibitors was performed.  486 
The in silico molecular docking of 4,532 compounds (representing a collection of 487 
both natural products and small fragment based structures (Suzuki and Miyata, 2006)) to the 488 
SmLSD1 target pocket resulted in the identification of seven compounds (L1-L7) that had a 489 
potential to interfere with the demethylase activity of this schistosome HDM (Supplementary 490 
Figure 1, Supplementary Table 3).  While we could commercially obtain compounds L1-L6, 491 
compound L7 was unavailable.  Therefore, prior to conducting whole organism anthelmintic 492 
screening (Figure 4), we identified and purchased three L7 analogues (L8, L9 and L10; 493 
Supplementary Table 3).  These analogues are previously characterised anthracyclines (L8 494 
– daunorubicin hydrochloride, L9 – doxorubicin hydrochloride, L10 – pirarubicin) with known 495 
antineoplastic activity (Minotti et al., 2004).  All 10 compounds displayed a higher predicted 496 
affinity for the target pocket found in SmLSD1 compared to HsLSD1 (PDB entry 2V1D) 497 
(Supplementary Table 5).   498 
 499 
3.4. In vitro screening of putative SmLSD1 interactors. 500 
Upon screening of the nine (L1-L6; L8-10) available compounds against schistosomula on 501 
the Roboworm platform (n = 2 wells per compound/120 schistosomula per well; 10 µM single 502 
point concentration), only L8 and L10 affected both parasite phenotype and motility metrics 503 
(Figure 4A); these two compounds were, thus, considered hits when compared to positive 504 
(auranofin (Kuntz et al., 2007)) and negative (DMSO) controls.  While the central scaffold 505 
structures of L8 (daunorubicin hydrochloride) and L10 (pirarubicin) are similar (Figure 4B), 506 
L10 is a C14-hydroxylated derivative of L8 containing a 4-tetrahydropyranyl substituent on 507 
the amino sugar in the C7 position of the central scaffold.  From this primary screen, L10 508 
appeared to be more potent than L8 against in vitro cultivated schistosomula (i.e. data points 509 
for L10 are closer to the origin in Figure 4A).  A subsequent dose response titration of both 510 
L10 and L8 confirmed this observation; EC50 values for both schistosomula motility and 511 
phenotype metrics were lower for L10 when compared to L8 (Figure 5).  This anthelmintic 512 
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trend (L10 > L8) was also observed for juvenile (3 wk old) schistosomes co-cultivated with 513 
both compounds (Figure 6).  The greater anthelmintic activity of L10 over L8 may be 514 
associated with potential increased membrane permeability (L10: LogP = 2.06; L8: LogP = 515 
1.83; Supplementary Table 3), structural differences in its sugar side chain (Supplementary 516 
Table 3 and (Denel-Bobrowska and Marczak, 2017)) or its ability to form an additional 517 
hydrogen bond with Asn653 due to the hydroxylic group in C14 within the target pocket of 518 
SmLSD1 (compare highlighted orange circles; Supplementary Figure 3).  Further medicinal 519 
chemistry investigations are necessary to disentangle these (or other) possibilities. 520 
We next explored the effect of both L10 and L8 on adult male and female 521 
schistosome pairs (7 wk old) (Figure 7).  Consistent with the schistosomula and juvenile 522 
worm screens, L10 displayed greater activity than L8 on adult worm motility (Figure 7A; L10 523 
EC50 = 14.18 µM, L8 EC50 > 50 µM).  While egg production was also affected by co-524 
cultivation with both compounds, L10 again demonstrated a more striking effect in inhibiting 525 
this critical process involved in host immunopathology and lifecycle transmission (Figure 526 
7B).  The higher EC50 recorded for adult parasites (14.18 µM) compared to schistosomula 527 
(1.5 µM for motility - 2.5 µM for phenotype; Table 1), despite greater Smlsd1 abundance in 528 
adults (Figure 2), suggested that L10 permeability/efflux could affect the activity of the 529 
compound in vitro or SmLSD1 function may differ across the schistosome lifecycle.   530 
Nevertheless, incubation of S. mansoni adult worms with the HAT inhibitors PU139, 531 
trichostatin A, valproic acid, sirtinol, salermide and MS3 also led to worm mortality or egg 532 
production defects (Dubois et al., 2009; Lancelot et al., 2013; Carneiro et al., 2014), further 533 
supporting a critical role for the careful regulation of histone post-translational modifications 534 
in adult (and other lifecycle stages) schistosome biological processes.   535 
As previously indicated, L10 was consistently more potent (compared to L8) in 536 
affecting schistosome phenotype or motility, regardless of lifecycle stage examined.  537 
Therefore, SEM analysis of adult male schistosomes co-cultivated in a sub-EC50 538 
concentration of this compound (12.5 µM) was performed to assess if L10 also affected 539 
surface worm morphology (Figure 7C).  Here, when compared to DMSO treated control 540 
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males, incubation of adult males in the presence of L10 led to the disruption and surface 541 
erosion of tegumental membranes.  This type of surface damage has been seen before and 542 
is consistent with stress and an inability to maintain molecular control of this protective 543 
barrier (Edwards et al., 2015; Crusco et al., 2018).  While we present molecular docking 544 
support suggesting that L10 interacts with the target pocket of SmLSD1 (Supplementary 545 
Figure 3) and, thus, affects histone demethylase activity, it is also possible that L10 546 
(pirarubicin) inhibits DNA and RNA synthesis, blocks transcription or produces membrane 547 
damaging free oxygen radicals as previously reported (reviewed in (McGowan et al., 2017)).  548 
Indeed, a degree of cytotoxicity was observed for L10 (and L8) using the surrogate human 549 
HepG2 cell line; however, there was a window of selectivity (i.e. selectivity index – 1.5 to 14) 550 
between this compound’s anthelmintic activity and general cytotoxicity (Table 1 and 551 
Supplementary Figure 4).  Anthracycline cytotoxicity and tumour specificity is a recognised 552 
phenomenon and represents an area of growing research in developing more selective 553 
antineoplastic compounds (Edwardson et al., 2015).  Nevertheless, a combination of 554 
multifactorial L10-mediated mechanisms of action (in addition to SmLSD1 inhibition) could 555 
be contributing to the anthelmintic stress response (s) observed (i.e. motility defects, surface 556 
damage and egg production inhibition); further investigations are required to tease apart 557 
L10’s inhibition of SmLSD1 versus other biological processes. 558 
 559 
3.5. RNAi of Smlsd1 in adult schistosomes. 560 
As a first step in progressing this objective, we undertook a functional genomics approach of 561 
SmLSD1 inhibition to see if aspects of L10-associated adult worm phenotypes could be 562 
recapitulated (Figure 8).  RNAi of adult (7 wk old) worm pairs, using Smlsd1 siRNAs, led to a 563 
significant reduction (56%, p = 0.001) in transcript abundance after 48 hr when compared to 564 
worm pairs treated with siluc siRNAs (Figure 8A).  At this time-point, egg production was 565 
also significantly inhibited (~50% reduced) in siSmlsd1 treated worms (Figure 8B).  While 566 
Smlsd1 transcript reduction (56%) and egg production inhibition (50%) at 48 hr is only 567 
correlated, the magnitude by which both processes were affected suggests a role for 568 
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SmLSD1.   After 7 days, siSmlsd1 treated worms recovered slightly, but were still producing 569 
far less eggs than their siluc counterparts (Figure 8B).  While this could reflect a sustained 570 
egg production defect carrying over from 48 hr, these results equally support a delay in 571 
normal egg production (compare the difference in eggs produced at the two timepoints 572 
between the two siRNA treatments).  Perhaps a more significant difference in egg 573 
production (between siSmlsd1 vs siluc treated worm pairs) would be observed if greater than 574 
56% knockdown in Smlsd1 was achieved and allow for these two scenarios to be resolved.  575 
Nevertheless, these functional genomics results, targeting Smlsd1, support the egg 576 
production defects mediated by L10 (Figure 7B) and validate the molecular targeting of this 577 
S. mansoni HDM for follow-on investigations. 578 
 579 
3.6. Conclusions. 580 
Here, we detail a strategy by which interdisciplinary approaches for pursuing drug discovery 581 
(bioinformatics, cheminformatics, whole organism screening and functional genomics) can 582 
be leveraged to identify next-generation schistosome chemotherapeutic targets.  By re-583 
classifying two opposing enzymatic families responsible for histone (and other protein) 584 
methylation and demethylation, we have identified SmLSD1 (and through homology, 585 
ShLSD1 – MS_02208 and SjLSD1 – Sjp_0082330; Supplementary Table 2) as a druggable 586 
candidate.  With the further repositioning of antineoplastic compounds (L8 - daunorubicin 587 
and L10 - pirarubicin) as putative SmLSD1 (and potentially ShLSD1 and SjLSD1) inhibitors, 588 
medicinal chemistry optimisation could lead to the generation of more potent and selective 589 
anti-schistosomals that negatively affect epigenetic processes underlying schistosome 590 
development and pathogenesis. 591 
  592 
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Figure legends 602 
 603 
Figure 1.  Re-description of Schistosoma mansoni histone methyltransferases (HMTs) 604 
and histone demethylases (HDMs).  (A)  Schematic mode of action representations for 605 
HMT and HDM epigenetic enzymes on nucleosome histones.  HMTs add a methyl group 606 
(Me) onto the N-terminal tails of histone proteins, whereas HDMs remove this chemical 607 
modification.  (B) Characteristic domains found within the HMT (PKMT, DOT1L, PRMT) and 608 
HDM (LSD, JMJD) families.  PKMT - Protein Lysine Methyltransferase, DOT1L - Disruptor of 609 
telomeric silencing 1-like, PRMT – Protein Arginine Methyltransferase, LSD -  Lysine 610 
Specific Demethylase, JMJD - Jumonji domain-containing protein, SET - Su(var)3-611 
9, Enhancer-of-zeste and Trithorax, AOL – amine oxidase-like, JmjN – Jumonji N terminal, 612 
JmjC – Jumonji C terminal.  (C)  Phylogenetic tree of S. mansoni HMTs and HDMs inferred 613 
from Neighbour-joining analysis using MEGA as described in the Materials and Methods. 614 
The analysis involved 27 HMT and 14 HDM Smps (Schistosoma mansoni proteins).  615 
Bootstrap support values on the nodes range from 0 to 25 (highlighted with ), between 26 616 
and 74 (highlighted with ) and between 75 and 100 (highlighted with ).  New HMTs and 617 
HDMs are highlighted in red boxes.  A colour code was used for each family of histone 618 
modifying enzymes: light blue for PKMT - Protein Lysine Methyltransferases, dark blue for 619 
PRDM – SET domain containing PR methyltransferase motifs, dark orange for DOT1L - 620 
Disruptor of telomeric silencing 1-like, light orange for PRMT – Protein Arginine 621 
Methyltransferases, dark blue for PRDM – PR Domain containing Methyltransferase, purple 622 
for LSD -  Lysine Specific Demethylases, green for JMJD - Jumonji domain-containing 623 
proteins. 624 
 625 
Figure 2.  S. mansoni hmts and hdms are differentially expressed throughout 626 
development.  DNA microarray analysis and heat map representation of (A) hmt and (B) 627 
hdm transcript abundance across 14 schistosome lifecycle stages. The expression level for 628 
each hmt or hdm was calculated as the ratio of individual log2 expression values (obtained 629 
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from (Fitzpatrick et al., 2009b)) to the median hmt or hdm log2 expression value  (red = up-630 
regulated; yellow = down-regulated).  Hierarchical clustering (Euclidean distance and 631 
complete linkage) of HMT and HDM Smp IDs (rows) are indicated on both panels. 632 
 633 
Figure 3.  Secondary and tertiary structural representations of Smp_150560, the 634 
closest S. mansoni ortholog of Homo sapiens Lysine Specific Demethylase (LSD) 1.  635 
(A) Characteristic LSD1 domains found in Smp_150560 (1164 AA) include a SWIRM 636 
(orange arrow) domain, an Amine Oxidase-Like (AOL, green) domain and a tower (blue) 637 
domain.  Amino acid length of each domain is provided.  (B) Homology model of 638 
Smp_150560 in complex with the cofactor FAD and substrate histone H3 protein (20 639 
residues fragment) produced using human LSD1 (PDB entry 2V1D) as the template.  640 
Domains are indicated and follow the colouring scheme in (A); FAD atoms are represented 641 
as spheres, histone H3 (methylated Lys is a yellow stick) is represented by yellow ribbon.  642 
Magnified target pocket (square) in SmLSD1 is represented as a surface model showing the 643 
histone (with methylated Lys) located in a channel connecting to the flavin adenine 644 
dinucleotide (FAD) cofactor (FAD shown as spheres: carbon (grey, oxygen (red), nitrogen 645 
(blue)). 646 
 647 
Figure 4.  In vitro schistosomula screen of putative SmLSD1 inhibitors.  (A) 648 
Mechanically-transformed schistosomula (n=120) were incubated with the putative SmLSD1 649 
inhibitors L1 - L6 and L8 - L10 (10 µM in 0.625% DMSO; each of them in duplicate) for 72 hr 650 
at 37 °C in a humidified atmosphere containing 5% C O2.  At 72 hr, the effect that each 651 
compound has on parasite phenotype and motility was assessed by the high throughput 652 
platform Roboworm. The graph shows the results of the anti-schistosomal activity of the 653 
selected compounds compared to DMSO (0.625%) and Auranofin (10 µM in 0.625% 654 
DMSO), respective negative and positive controls (average of 24 different replicate 655 
wells/control).  Compounds with activity on both schistosomula phenotype and motility are 656 
shown within the ‘Hit Zone’ (delineated by the dotted lines in the graph).  Z´ scores (Zhang et 657 
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al., 1999) for these screens are included on the graph.  (B) Chemical structures of the two 658 
compounds (L8 and L10) showing the strongest anti-schistosomula activity. 659 
 660 
Figure 5.  Dose response titrations of L10 and L8 against schistosomula.  The two hit 661 
compounds were screened against mechanically-transformed schistosomula at 10 µM and 662 
lower concentrations (5 µM, 2.5 µM, 1.25 µM and 0.625 µM) as described in Figure 4. Three 663 
independent dose response titrations were performed and each compound concentration 664 
was evaluated in duplicate. Dose response curves for S. mansoni schistosomula phenotype 665 
and motility were prepared using GraphPad Prism (mean +/- SD of mean is indicated for 666 
each compound concentration).  Estimated EC50s calculated from these dose response 667 
curves are summarized in the table.  Z´ scores (Zhang et al., 1999) for these three repeat 668 
titrations were 0.40 for motility and 0.30 for phenotype.  669 
 670 
Figure 6. Compounds L10 and L8 affect juvenile worm motility.  Juvenile S. mansoni 671 
worms (3 weeks post infection; n = 10 - 25) were cultured in different concentrations of L10 672 
or L8 (20 µM, 15 µM, 10 µM, 5 µM, 2.5 µM and 1.25 µM in 1.25% DMSO) and motility 673 
scored (0 = dead, 4 = normal movement) at 72 hr.  Average scores/treatment are indicated 674 
on top of the stacked histograms with percentages of worms displaying the phenotype 675 
scored represented by different colour/textural combinations.  Control parasites (n = 10 - 25) 676 
included those co-cultivated in the presence of 1.25 % DMSO and PZQ (10 µM in 1.25% 677 
DMSO).  Estimated EC50s calculated from these dose response titrations are summarized in 678 
the table. 679 
 680 
Figure 7.  Compounds L10 (and L8) affect adult worm motility, egg production and 681 
tegumental surface architecture.  Adult schistosome pairs (7 wk old, 3 pairs/well) were co-682 
cultivated with L10 and L8 (two-fold titrations between 50 µM-6.25 µM) for 72 h at 37 °C in a 683 
humidified atmosphere containing 5% CO2. The effect on schistosome motility (A) and egg 684 
production (B) was quantified as described in the Materials and Methods section. The 685 
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stacked bars represent the percentages of worms displaying the phenotype scored and are 686 
represented by different colour/textural combinations; the average motility score (6 worms 687 
for each of the three independent experiments) is indicated above each bar.  Control 688 
parasites (n = 6) included those co-cultivated in the presence of 1.25% DMSO and PZQ (10 689 
µM in 1.25% DMSO). *, **, ***, **** represent p < 0.05, p < 0.01, p < 0.001, p < 0.0001, 690 
respectively. Estimated EC50s calculated from these dose response titrations are 691 
summarized in the table.  (C)  SEM analysis of adult male worms cultivated in a sub-EC50 692 
concentration of L10 (12.5 µM in 1.25% DMSO) compared to DMSO controls (1.25%). 693 
 694 
Figure 8.  RNAi-mediated knockdown of Smlsd1 affects the in vitro production of 695 
schistosome eggs.  (A) Seven-week old adult male and female schistosomes were 696 
electroporated with 5 µg siRNA duplexes targeting luciferase (siLuc) or Smlsd1 (siSmlsd1).  697 
Following 48 hr, total RNA was harvested and subjected to qRT-PCR.  Percent knockdown 698 
(KD) and statistical significance (Student’s t test, two tailed, unequal variance) is indicated.  699 
All siRNA and qRT-PCR DNA sequences are included in Supplementary Table 4.  (B) Egg 700 
production at 48 and 168 hr after introduction of siRNAs.  Statistical significance is indicated 701 
(Student’s t test, two tailed, unequal variance).  * represents p < 0.05, ** represents p < 0.01 702 
and *** represents p < 0.001.   703 
 704 
 705 
  706 
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Table 1.  L8 and L10 antischistosomal activity and cytotoxicity summary.
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Highlights 
 
- Schistosoma mansoni contains 27 histone methyltransferases (HMTs) and 14 
histone demethylases (HDMs). 
- S. mansoni lysine specific demethylase 1 (SmLSD1) is a druggable target. 
- Schistosomes treated with the putative SmLSD1 inhibitor pirarubicin or small 
interfering RNAs targeting SmLSD1 are less fecund.  
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